Home > Journals > Biology and research > European Cytokine Network > summary
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
Biology and research
European Cytokine Network
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
Printable version

New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis.


European Cytokine Network. Volume 9, Number 3, 233-8, September 1998, Synthèses

Free Article  

Author(s) : F. BREEDVELD

Summary : Continued research towards new and better tolerated therapies to attenuate the inflammation and pain associated with rheumatoid arthritis and to halt the progression of erosive joint damage has led to the development of anticytokine strategies. Of these therapies, the most promising appear to be those targeted towards blocking the effects of TNF-alpha. Trials with etanercept, which showed significant, rapid and sustained reductions in disease activity, have produced particularly encouraging results.

Keywords : rheumatoid arthritis, cytokines, tumor necrosis factor.

 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]